Beta Bionics (NASDAQ:BBNX) Coverage Initiated at Leerink Partners

Stock analysts at Leerink Partners initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report issued on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $28.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 36.12% from the company’s current price.

Several other brokerages have also issued reports on BBNX. Robert W. Baird started coverage on Beta Bionics in a research report on Thursday. They set a “neutral” rating and a $20.00 target price for the company. LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a research report on Thursday. They set a “neutral” rating and a $20.00 price objective for the company. Finally, Baird R W raised Beta Bionics to a “hold” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $23.80.

Beta Bionics Trading Down 1.4 %

BBNX stock opened at $20.57 on Monday. Beta Bionics has a 52-week low of $20.57 and a 52-week high of $24.50.

Insider Activity

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the purchase, the insider now owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the purchase, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.